Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

PR Newswire December 20, 2023

Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting

PR Newswire December 11, 2023

Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

PR Newswire November 13, 2023

Moleculin Reports Third Quarter 2023 Financial Results

PR Newswire November 13, 2023

Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast

PR Newswire November 7, 2023

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

PR Newswire November 6, 2023

Moleculin to Participate in the Virtual Investor Ask the CEO Conference

PR Newswire October 11, 2023

Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

PR Newswire October 2, 2023

Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

PR Newswire September 21, 2023

Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

PR Newswire September 18, 2023

Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

PR Newswire September 14, 2023

Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PR Newswire September 5, 2023

Moleculin Reports Second Quarter 2023 Financial Results

PR Newswire August 11, 2023

Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

PR Newswire August 10, 2023

Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling

PR Newswire August 7, 2023

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast

PR Newswire August 3, 2023

Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

PR Newswire July 13, 2023

Moleculin to Participate in the Virtual Investor Summer Spotlight Series

PR Newswire July 6, 2023

Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

PR Newswire June 13, 2023

Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023

PR Newswire May 30, 2023